PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer
PDS Biotechnology Co. (NASDAQ: PDSB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
PDS Biotechnology Co. (NASDAQ: PDSB) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
PDS Biotech to Participate in Upcoming May 2024 Investor Conferences
PDS Biotech to Announce First Quarter 2024 Financial Results on May 15, 2024